이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Boston Scientific 관리
관리 기준 확인 3/4
Boston Scientific's CEO는 Mike Mahoney, Oct2011 에 임명되었습니다 의 임기는 12.67 년입니다. 총 연간 보상은 $ 18.72M, 7.5% 로 구성됩니다. 7.5% 급여 및 92.5% 보너스(회사 주식 및 옵션 포함). 는 $ 146.21M 가치에 해당하는 회사 주식의 0.13% 직접 소유합니다. 146.21M. 경영진과 이사회의 평균 재임 기간은 각각 8.2 년과 8 년입니다.
주요 정보
Mike Mahoney
최고 경영자
US$18.7m
총 보상
| CEO 급여 비율 | 7.5% |
| CEO 임기 | 12.7yrs |
| CEO 소유권 | 0.1% |
| 경영진 평균 재임 기간 | 8.2yrs |
| 이사회 평균 재임 기간 | 8yrs |
최근 관리 업데이트
Recent updates
Should You Investigate Boston Scientific Corporation (NYSE:BSX) At US$77.00?
Jun 21
Boston Scientific Has Become A Standout Growth Story In Med-Tech
Jun 13Why We're Not Concerned About Boston Scientific Corporation's (NYSE:BSX) Share Price
Jun 08Is Boston Scientific (NYSE:BSX) Using Too Much Debt?
May 10Boston Scientific (NYSE:BSX) Is Reinvesting At Lower Rates Of Return
Apr 22Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash
Apr 05A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Mar 26We Ran A Stock Scan For Earnings Growth And Boston Scientific (NYSE:BSX) Passed With Ease
Feb 29What You Can Learn From Boston Scientific Corporation's (NYSE:BSX) P/E
Feb 15Is Boston Scientific (NYSE:BSX) A Risky Investment?
Feb 02Boston Scientific (NYSE:BSX) Could Be Struggling To Allocate Capital
Jan 19Boston Scientific: Portfolio Updates Driving Top-Line Growth
Jan 17Boston Scientific: Continued M&A Drives More Growth
Jan 10Is Boston Scientific Corporation (NYSE:BSX) Worth US$56.1 Based On Its Intrinsic Value?
Dec 04Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?
Nov 03Boston Scientific: Delivering Strong Growth, But Sector Derating Is A Big Issue
Oct 30ADVENT Offers Up An Early Present For Boston Scientific Investors
Aug 28Estimating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Aug 24Boston Scientific (NYSE:BSX) Seems To Use Debt Quite Sensibly
Jul 25Boston Scientific Remains Operationally Sound But May Have Limited Upside
Jul 14Investors Could Be Concerned With Boston Scientific's (NYSE:BSX) Returns On Capital
Jul 10Boston Scientific Corporation (NYSE:BSX) Shares Could Be 29% Above Their Intrinsic Value Estimate
May 21Here's Why Boston Scientific (NYSE:BSX) Can Manage Its Debt Responsibly
Apr 18Returns On Capital At Boston Scientific (NYSE:BSX) Paint A Concerning Picture
Apr 03Boston Scientific Stands Out With Strong, Diversified Growth Profile
Feb 15Boston Scientific Non-GAAP EPS of $0.45 misses by $0.02, revenue of $3.24B in-line
Feb 01Boston Scientific sees double digit EPS growth in 2023 - JPMorgan Healthcare conference
Jan 11Boston Scientific to acquire majority stake of Acotec Scientific
Dec 12CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$2b |
| Dec 31 2023 | US$19m | US$1m | US$2b |
| Sep 30 2023 | n/a | n/a | US$1b |
| Jun 30 2023 | n/a | n/a | US$861m |
| Mar 31 2023 | n/a | n/a | US$846m |
| Dec 31 2022 | US$17m | US$1m | US$642m |
| Sep 30 2022 | n/a | n/a | US$596m |
| Jun 30 2022 | n/a | n/a | US$828m |
| Mar 31 2022 | n/a | n/a | US$754m |
| Dec 31 2021 | US$16m | US$1m | US$985m |
| Sep 30 2021 | n/a | n/a | US$1b |
| Jun 30 2021 | n/a | n/a | US$526m |
| Mar 31 2021 | n/a | n/a | US$201m |
| Dec 31 2020 | US$14m | US$667k | -US$115m |
| Sep 30 2020 | n/a | n/a | US$4b |
| Jun 30 2020 | n/a | n/a | US$4b |
| Mar 31 2020 | n/a | n/a | US$4b |
| Dec 31 2019 | US$16m | US$1m | US$5b |
| Sep 30 2019 | n/a | n/a | US$1b |
| Jun 30 2019 | n/a | n/a | US$1b |
| Mar 31 2019 | n/a | n/a | US$2b |
| Dec 31 2018 | US$14m | US$1m | US$2b |
| Sep 30 2018 | n/a | n/a | US$670m |
| Jun 30 2018 | n/a | n/a | US$521m |
| Mar 31 2018 | n/a | n/a | US$112m |
| Dec 31 2017 | US$13m | US$1m | US$104m |
보상 대 시장: Mike 의 총 보상 ($USD 18.72M )은 US 시장( $USD 13.50M ).
보상과 수익: Mike 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Mike Mahoney (59 yo)
12.7yrs
테뉴어
US$18,723,735
보상
Mr. Michael F. Mahoney, also known as Mike, has been Independent Director of CVS Health Corporation since November 01, 2023. He has been Chairman of Boston Scientific Corporation since May 3, 2016, and is...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairman | 12.7yrs | US$18.72m | 0.13% $ 147.5m | |
| Executive VP & CFO | 10.4yrs | US$5.83m | 0.015% $ 17.2m | |
| Executive VP & Group President of Cardiology | 14.3yrs | US$5.59m | 0.013% $ 15.0m | |
| Executive VP & President of Peripheral Interventions | 11.4yrs | US$3.78m | 0.0019% $ 2.2m | |
| Executive VP and Group President of MedSurg & Asia Pacific | 7.9yrs | US$4.27m | 0.0015% $ 1.8m | |
| Executive Vice President of Global Operations | 2.1yrs | 데이터 없음 | 0.0036% $ 4.1m | |
| Senior VP | less than a year | 데이터 없음 | 0.00026% $ 294.4k | |
| Senior VP and Chief Information & Digital Officer | 8.5yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP of Investor Relations | less than a year | 데이터 없음 | 0.0026% $ 2.9m | |
| Senior VP | 3yrs | 데이터 없음 | 0.0022% $ 2.5m | |
| Senior VP of Market Access & Chief Marketing Officer | 3.1yrs | 데이터 없음 | 데이터 없음 | |
| Executive Vice President of Human Resources | 11.5yrs | 데이터 없음 | 0.0031% $ 3.5m |
8.2yrs
평균 재임 기간
56yo
평균 연령
경험이 풍부한 관리: BSX 의 관리팀은 노련하고 경험 (평균 재직 기간 8.2 년)입니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| Chairman | 11.6yrs | US$18.72m | 0.13% $ 147.5m | |
| Lead Independent Director | 10.3yrs | US$360.00k | 0.0030% $ 3.4m | |
| Independent Director | 8.2yrs | US$335.00k | 0.0033% $ 3.7m | |
| Independent Director | 7.9yrs | US$320.00k | 0.00020% $ 226.4k | |
| Independent Director | 3yrs | US$338.75k | 0.0027% $ 3.0m | |
| Director | less than a year | 데이터 없음 | 데이터 없음 | |
| Independent Director | 9.2yrs | US$326.25k | 0.0043% $ 4.8m | |
| Independent Director | 15.2yrs | US$340.00k | 0.0036% $ 4.1m | |
| Independent Director | less than a year | US$233.23k | 0.00042% $ 475.5k | |
| Independent Director | less than a year | US$233.23k | 0.00027% $ 305.7k |
8.0yrs
평균 재임 기간
61yo
평균 연령
경험이 풍부한 이사회: BSX 의 이사회는 경험(평균 재직 기간 8 년)으로 간주됩니다.